SELLAS Life Sciences Group (SLS) reported a Q1 loss late Tuesday of $0.05 per diluted share, narrowing from a loss of $0.07 a year earlier.
Two analysts polled by FactSet expected a loss of $0.06.
Cash and cash equivalents were $107.1 million at the end of Q1, compared with $71.8 million at the end of Q4.
Shares of the company rose more than 12% in after-hours activity.